Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | GLP1R | P43220 | 8/20 | 0.49 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19308032 | 1.00 | NOD1 (0.55) | NOD1EPHX2GLP1RGLO1PTPN1 | |
| SCHEMBL21242900 | 0.94 | NOD1 (0.59) | NOD1EPHX2GLP1RGLO1PTPN1 | |
| SCHEMBL21242674 | 0.94 | NOD1 (0.59) | NOD1EPHX2GLP1RGLO1PTPN1 | |
| SCHEMBL14167624 | 0.94 | NOD1 (0.59) | NOD1EPHX2GLP1RGLO1PTPN1 | |
| SCHEMBL19776963 | 0.94 | NOD1 (0.59) | NOD1EPHX2GLP1RGLO1PTPN1 | |
| SCHEMBL24178469 | 0.94 | NOD1 (0.59) | NOD1EPHX2GLP1RGLO1PTPN1 | |
| SCHEMBL16273259 | 0.91 | NOD1 (0.59) | NOD1EPHX2GLP1RFOLH1 | |
| SCHEMBL19308060 | 0.91 | NOD1 (0.52) | NOD1EPHX2GLP1RFOLH1KDM4E | |
| SCHEMBL19307981 | 0.89 | NOD1 (0.55) | NOD1EPHX2GLP1RFOLH1 | |
| SCHEMBL20215729 | 0.89 | NOD1 (0.55) | NOD1EPHX2GLP1RFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044394-A1 | STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE | NOVO NORDISK AS (DK) | 2018-02-15 | — | — | US | disclosed |
| US-9751927-B2 | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use | NOVO NORDISK A/S (DK) | 2017-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044394-A1 | STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE | GLP1R, GIPR, GCGR | NOD1 1398/4885EPHX2 4147/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.